The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Abroad (travel likely)Recruiting

Conditions

Relapsing Remitting Multiple Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shepherd Center, Atlanta, Georgia, United States
Contact: Study coordinator (Michelle Tidwell) · Michelle.Tidwell@shepherd.org · 404-367-1317
Contact: Study coordinator (Cathy Furbish) · Cathy.Furbish@shepherd.org · 404-350-7591
Contact: Principal Investigator (Jacqueline Rosenthal, MD)
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Contact: Study coordinator (Adam Didouchevski) · adidouc1@jh.edu · 443-818-1451
Contact: Principal Investigator (Bardia Nourbakhsh, MD)
Minnesota Center for Multiple Sclerosis, Plymouth, Minnesota, United States
Contact: Study coordinator (Halie Kaufman) · HKaufman@vivoinfusion.com · 763-243-8180
Contact: Principal Investigator (Jonathan Calkwood, MD)
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Contact: Study coordinator (Tanya Khan) · Tanya.S.Khan@uth.tmc.edu · 713-704-0823
Contact: Principal Investigator (John Lincoln, MD)
UW Medicine Multiple Sclerosis Center-Northwest, Seattle, Washington, United States
Contact: Study coordinator (Elisa McGee) · emcgee@uw.edu · 206-598-9260
Contact: Principal Investigator (Yujie Wang, MD)
West Virginia University, Morgantown, West Virginia, United States
Contact: Study coordinator (Lauren Chase) · lauren.chase@wvumedicine.org · 304-598-4000
Contact: Principal Investigator (Melanie Ward, MD)

View source on ClinicalTrials.gov Contact study team (email)